NCT07411274

Brief Summary

Although scalp nerve blocks have been shown to provide effective postoperative analgesia in pediatric neurosurgical procedures, limited data exist on their use under ultrasound guidance. The smaller anatomical structures and higher vascularity of the pediatric scalp increase the risk of inadvertent vessel puncture or systemic toxicity with landmark-based techniques. Ultrasound guidance enables direct visualization of the targeted nerves and adjacent vessels, potentially improving block accuracy and safety. To date, no randomized controlled trial has compared ultrasound-guided versus conventional scalp block specifically in pediatric supratentorial tumor surgeries. This study aims to fill this gap.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
74

participants targeted

Target at below P25 for phase_3

Timeline
5mo left

Started Feb 2026

Shorter than P25 for phase_3

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress40%
Feb 2026Oct 2026

First Submitted

Initial submission to the registry

January 26, 2026

Completed
6 days until next milestone

Study Start

First participant enrolled

February 1, 2026

Completed
12 days until next milestone

First Posted

Study publicly available on registry

February 13, 2026

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2026

Last Updated

February 13, 2026

Status Verified

January 1, 2026

Enrollment Period

8 months

First QC Date

January 26, 2026

Last Update Submit

February 11, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Mean arterial blood pressure intraoperatively from baseline till skin incision

    The mean arterial blood pressure recorded during 5 minutes immediately before skin incision till the peak mean arterial blood pressure recorded within the first minute after incision

    from 5 minutes immediately before skin incision till the peak mean arterial blood pressure recorded within the first minute after incision

Secondary Outcomes (4)

  • Duration of analgesia

    24 hours postoperatively

  • objective pain scale

    2, 4, 6, 8, 12, 16, and 24 hours postoperatively

  • Total doses of ketorolac

    24 hours postoperatively

  • 6. Total dose of paracetamol

    24 hours postoperatively

Study Arms (2)

Ultrasound-guided scalp block using bupivacaine

ACTIVE COMPARATOR

patients will recieve ultrasound-guided scalp block using bupivacaine

Procedure: Ultrasound-guided scalp block

conventional scalp block using bupivacaine

ACTIVE COMPARATOR

patients will recieve conventional scalp block with bupivacaine using a landmark-based technique

Procedure: conventional scalp block

Interventions

Patients will receive ultrasound-guided scalp block using bupivacaine 0.25% at 0.1-0.2 mL/kg per nerve site, not exceeding a total dose of 2.5 mg/kg.

Ultrasound-guided scalp block using bupivacaine

Patients will receive conventional scalp block using landmark-based technique with bupivacaine 0.25% at 0.1-0.2 mL/kg per nerve site, not exceeding a total dose of 2.5 mg/kg.

conventional scalp block using bupivacaine

Eligibility Criteria

Age2 Years - 12 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • American Society of Anesthesiologists (ASA) physical status I, II.
  • Undergoing elective supratentorial tumor surgery under general anesthesia on one side of the head.

You may not qualify if:

  • Urgent/emergency craniotomy.
  • Coagulopathy or platelet dysfunction.
  • Allergy to local anesthetics.
  • Pre-existing bradycardia (HR \<60 bpm in infants, \<50 bpm in older children) or unstable arrhythmias.
  • Severe hepatic/renal impairment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Pain, Postoperative

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer of anaesthesia

Study Record Dates

First Submitted

January 26, 2026

First Posted

February 13, 2026

Study Start

February 1, 2026

Primary Completion (Estimated)

October 1, 2026

Study Completion (Estimated)

October 1, 2026

Last Updated

February 13, 2026

Record last verified: 2026-01